Psoriasis is characterized by hyperproliferation of keratinocytes and dermal infiltration by activated T cells, neutrophils, and dendritic cells. Psoriasis involves keratinocytes, antigen-presenting cells, neutrophilic granulocytes, vascular endothelial cells, and the cutaneous nervous system. The infiltrated psoriatic lesions have significantly increased levels of the CD4 T-cell subsets T helper (Th1 and Th17). The contribution of distorted immune activation has been proved to target some key immune components, namely IL-23, tumor necrosis factor alpha, and the Th17/IL-23 axis. The infiltrated psoriatic lesions have significantly increased levels of the CD4 T-cell subsets T helper (Th)1 and Th17. The immune genes are responsible for several functions that involve innate immunity, antigen presentation, the interleukin (IL)-23 axis, and T-cell development and polarization. In recent years, the contribution of some of these gene products to psoriasis has been proved to target some key immune components, namely IL-23, tumor necrosis factor alpha (TNF-α), and the Th17/IL-23 axis. TNF-α is a pro-inflammatory cytokine, produced by different cell types including lymphocytes, keratinocytes, endothelial cells, and macrophages, which amplifies inflammation response through several pathways. The IL-23/Th17 axis could be a novel targeted therapy for the treatment of psoriasis. Th17 cells are a subset of T-lymphocytes that express IL17, different from the classical Th17 cells, that have a significant role in the pathogenesis of inflammatory disorders including psoriasis.
Due to the side effects and safety concerns of the long-term use of therapies, treatment selection is challenging. An increasing number of psoriatic patients are seeking alternative therapies.
Patients with moderate psoriasis identified IL-17 as a key pathway that can be modulated by treatment with Indigo naturalis. Clinical studies have demonstrated that Indigo naturalis used as topical monotherapy is efficacious in treating patients with mild-to-moderate psoriasis, although the validity of these studies is challenged by intra-patient treatment comparison designs. One component of Indigo naturalis, indirubin, was reported to inhibit cyclin-dependent kinase and signal transducer and activator of transcription-3 (STAT3) activities, and keratinocyte proliferation. Moreover, Indigo naturalis extract has been shown to inhibit oxygen generation and elastase release in formyl-methionyl-leucylphenylalanine- induced human neutrophils in vitro. Indigo naturalis significantly down-regulated the IL-17 pathway in affected skin, similar to other therapies that successfully target this pathway. Moreover, we showed that one of the chemical components in Indigo naturalis, tryptanthrin, possesses moderate anti-IL-17 activity.
Curcumin is a polyphenol derived from the golden spice turmeric (“Curcuma longa”). Because of its numerous properties (e.g. anti – oxidant, anti -proliferative, anti-inflammatory), curcumin has been used for the treatment of psoriasis. The anti-inflammatory properties of curcumin have been showed in the serum as a decrease of more than 50% in the level of inflammatory factors, including TNF – α, IFN – γ, IL – 2, IL – 12, IL – 22 and IL – 23.
Argemone mexicana plant, and the fractions obtained from leaves and stem of Argemone mexicana plant, exhibit immunosuppression, lymphoproliferation inhibition, cytokine modulation such as IL-2 inhibition, IFN-g inhibition, IL-10 induction, keratinocyte proliferation inhibition, keratolytic activity, endothelial cell proliferation inhibition, inhibition of cell adhesion molecule expression such as ICAM-1, MEST inhibition, and enzymes inhibition such as p60src Tyrosine kinase, which are known to be involved in anti-psoriatic activity and the usefulness of the extracts and fractions for the treatment and prevention of skin ailments such as psoriasis including plaque psoriasis, guttate psoriasis, pustular psoriasis and psoriasis of the nails. Thymol and carvacrol suppress an antigen-specific immune response in vivo, in part, by inducing reductions in TH1, TH2 and TH17 cell-related cytokines and key transcription factors involved in their differentiation. TREGULATE is an herbal tablet to control psoriasis skin scale problems, psoriasis arthritis, chronic inflammation to control autoimmune disease. TREGULATE has a combination of immune correcting herbal formulation for controlling psoriasis scaling, itching problem of skin due to autoimmune disorder. The formulation is designed to normalize skin immune system and repair local tissue damage. TREGULATE restores immune system by selective immune-modulation and promotes T regulatory cells to reduce skin hyper proliferation and chemokines production. TREGULATE increases CD4+CD25+Foxp3+ regulatory T Cells and also inhibits IL-17 and IL23 over production, TREGULATE arrests the progress of disease and prevents further deterioration of disease conditions and improves quality of life.
Psoriasis, itchy skin, scaling, lesions, redness, thick patchy and silvery scales, eczema, pruritus, dermatitis and other chronic inflammatory skin ailments
1 tablet morning 30 minutes before meal and 1 tablet night before bed time
Argemone mexicana, Silybum marianum, Cuminum cyminum, Glycyrrhiza glabra, Thymus vulgaris, Indigofera tinctoria.
Safe to use for children and adults. No side effects and allergies.